Fractures Clinical Trial
Official title:
A Prospective Randomized Double Blind Evaluation of Ketamine/Propofol vs Ketamine Alone for Pediatric Extremity Fracture Reduction
The objective of this study is to compare Ketamine-Propofol with Ketamine-only in a double-blind, randomised, controlled trial in a paediatric emergency department. We believe that the combination of these two agents will provide a new and more effective option for procedural sedation in paediatric emergency department patients. The hypothesis of the study is that paediatric emergency department patients requiring procedural sedation for an isolated orthopaedic injury with Ketamine-Propofol will have reduced total sedation time, time to recovery, complications and improved satisfaction scores compared to patients receiving Ketamine alone.
Purpose: Procedural sedation has become an essential skill for emergency physicians, allowing
for completion of painful procedures in a safe, comfortable and efficient manner. The ideal
sedative agent would allow for an effective level of sedation, rapid onset and offset,
absence of hemodynamic or respiratory compromise, and lack of post procedural side effects. A
variety of agents have been studied for paediatric procedural sedation, however no currently
used agent meets all of these criteria (1).
Background: Ketamine and Propofol are two agents that have been well studied and are commonly
utilized as single agents for sedation. Ketamine is a dissociative agent that has amnestic
and analgesic qualities. It has the unique property of allowing for deep sedation with
minimal effects on the patient's respiratory drive. Ketamine use does not cause hypotension
and in fact can have a positive effect on blood pressure. Ketamine has been extensively
studied in paediatric sedation and has been found to be a safe and effective (2,3,4). Side
effects associated with Ketamine use include post procedural nausea and vomiting, and
unpleasant emergence phenomena such as agitation or hallucinations. Ketamine sedation can
result in prolonged recovery times compared to other sedative agents and has a low rate of
respiratory depression, apnea and laryngospasm (1).
Propofol is a sedative-hypnotic agent that has been popular for use in adult and paediatric
procedural sedation for over a decade. The agent's rapid onset of effect and short duration
of action allow for efficient sedation and recovery. Propofol has antiemetic properties and
post-procedural side effects are rare. Caution must be used with Propofol, as it can be
associated with significant respiratory depression and/or hypotension (1). The prolonged use
of Propofol in children can produce acidosis, but this is not a problem for single use for an
acute painful procedure.
A number of studies have demonstrated that the combination of Ketamine and Propofol for
sedation is safe and effective, with most of the data in adults or in adult-child studies
with small number of children (5,6). The combination of the two agents appears to reduce side
effects of each medication used alone, and allows for a rapid recovery time. A prospective
case series of Canadian emergency department patients given Ketamine-Propofol for procedural
sedation has recently been published (5). In this study, 22% of the patients were children.
However, to date there has been no targeted research published comparing Ketamine-Propofol
head to head with any other presently utilized sedation regimen in a paediatric emergency
department setting.
Objective & Hypothesis: The objective of this study is to compare Ketamine-Propofol with
Ketamine-only in a double-blind, randomised, controlled trial in a paediatric emergency
department. We believe that the combination of these two agents will provide a novel and more
efficacious option for procedural sedation in paediatric emergency department patients. The
hypothesis of the study is paediatric emergency department patients requiring procedural
sedation for an isolated orthopaedic injury with Ketamine-Propofol will have reduced total
sedation time, time to recovery, complications and improved satisfaction scores compared to
patients receiving Ketamine alone.
Experimental Design: This study will be a prospective, double-blind, randomised, controlled
clinical trial with an expected enrolment of approximately 140 patients from June-October
2007.
n = 2 * (Z1-α/2 + Z1-β)2 * σ2 / ∆2
n = 2 * (1.96 + 0.84)2 * 202 / 102
n = 2 * 7.84 * 400 / 100
n = 62.7 or 63 per group
Based on the calculation above, 63 children are needed in each group to have an 80% chance of
detecting a clinically meaningful difference in total sedation time of 10 minutes between the
groups, assuming an alpha of 0.05, and a standard deviation of 20 minutes. We have added an
additional 7 patients (10%) to each group to account for potential drop-outs. Written,
informed consent will be obtained from a parent/guardian for all children that meet the study
inclusion criteria. Additionally, all children over the age of eight will also be asked for
their assent.
Interventions: After giving informed consent, eligible patients will be assigned to either
the Ketamine-Propofol group or Ketamine-placebo group through random allocation. Sealed
envelopes containing a randomized assignment to either Ketamine-Propofol or Ketamine-only
group will be prepared by an individual unconnected with the study using a web-based random
number generator, balanced to ensure equal allocation to each group.
Patients in the Ketamine-only group will receive an intravenous dose of 1.0 mg/kg Ketamine
and patients in the Ketamine-Propofol group will receive an intravenous dose of 0.5 mg/kg
Ketamine and 1.0 mg/kg Propofol at time zero. Two minutes after the initial dose of sedative
agent, and every 2 minutes thereafter, the attending physician will assess the patient's
level of sedation using the Children's Hospital of Wisconsin Sedation Scale (Appendix A). If
the attending physician determines the level of sedation is not adequate (Sedation score ≥
3), additional study drugs (Ketamine group: 0.25 mg/kg Ketamine; Ketamine-Propofol group: 0.5
mg/kg Propofol) will be administered every 2 minutes until adequate sedation is achieved
(deep conscious sedation = Children's Hospital of Wisconsin Sedation Scale Score < 3). Once a
sedation score < 3 is achieved, the procedure will begin.
All sedation will be performed under continuous cardiorespiratory monitoring based on current
hospital guidelines under the care and surveillance of a pediatric emergency department
registered nurse and physician. Vital signs including heart rate, blood pressure, respiratory
rate and oxygen saturation will be monitored continuously and recorded every 2 minutes, with
the exception of blood pressure, which will be recorded every 4 minutes. The assisting
registered nurse will also record information regarding time of last liquid and solid intake
and body weight on the hospital's standard procedural sedation and analgesia record form.
A separate, standardized datasheet (Appendix B) will be used to collect the time when the
study drug was first administered, the time when the procedure began, the time the procedure
was completed and the time to recovery. Upon completion of the procedure, a recovery score
based on a modified Aldrete Scale, will be recorded by a research associate blinded as to the
intervention used every 2 minutes until full recovery, defined as a minimum cumulative score
of 8. The attending physician will be asked to document any complications (including
hypotension, apnea, hypoxia, laryngospasm and pain on injection) that occurred during the
procedure and if any interventions were necessary. The nurse caring for the patient will also
record any adverse events (nausea, vomiting, agitation) that occurred during recovery.
Outcome Measures: The primary outcome will be total sedation time, defined as the time that
the first study drug was injected until the patient is fully recovered with a minimum
recovery score ≥ 8. Secondary outcomes will include time to recovery; patient, nurse, and
physician satisfaction; complications and adverse events. The patient, nurse and physician
will be asked to individually assess their level of satisfaction with the sedation procedure
using a 7-point Likert scale (Appendices C-E).
Analyses Strategy: The independent samples t-test will be used to compare differences in mean
total sedation time and recovery time between the Ketamine and Ketamine-Propofol groups. The
Mann-Whitney test will be used to compare differences in satisfaction levels (measured on an
ordinal scale) between groups. Differences in proportions of complications during the
procedure and adverse events during recovery will be assessed by the Chi-Square test between
groups. A p value <0.05 will be considered statistically significant.
Expectation: The expectation of the study is paediatric emergency department patients
requiring procedural sedation for an isolated orthopaedic injury with Ketamine-Propofol will
have reduced total sedation time, time to recovery, complications and improved satisfaction
scores compared to patients receiving Ketamine alone.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00137085 -
Ketamine Versus Fentanyl as an Adjunct to Propofol-Assisted Emergency Department Procedural Sedation
|
N/A | |
Completed |
NCT00152321 -
Strategies Targeting Osteoporosis to Prevent Recurrent Fractures
|
N/A | |
Completed |
NCT00235404 -
Randomized Controlled Trial of Health Care to Elderly Patients.
|
N/A | |
Completed |
NCT01127711 -
Cohort of Swedish Men
|
N/A | |
Completed |
NCT00060970 -
Evaluating Muscle Function After Ankle Surgery
|
N/A | |
Completed |
NCT02576730 -
Functional Outcome Assessment After (Calcaneal) Trauma Surgey
|
N/A | |
Completed |
NCT02074969 -
Intramedullary Devices for the Treatment of Unstable Pertrochanteric Fractures
|
N/A | |
Withdrawn |
NCT00355420 -
Evaluation of the Change in Length of the Leg in Children After Treatment of Femur Fractures.
|
Phase 2 | |
Completed |
NCT00767780 -
The Effect of a New Biomechanical Device
|
N/A | |
Completed |
NCT00129142 -
Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy
|
Phase 3 | |
Terminated |
NCT03367169 -
Surgery of the Pilon Fractures
|
N/A | |
Active, not recruiting |
NCT01452243 -
Prevention of Falls and Fractures in Old People by Administration of Calcium and Vitamin D. Randomized Clinical Trial
|
Phase 3 | |
Completed |
NCT00545350 -
Exercise Intervention to Prevent Fall-related Fractures and Other Injuries : The Ossébo Study
|
N/A | |
Terminated |
NCT00387686 -
A Phase 2/3 Multicenter, Controlled Trial Of rhBMP-2/CPM In Tibial Fractures
|
Phase 2/Phase 3 | |
Completed |
NCT02292316 -
Falls With Fracture : Role of Cognitive Disorders and Comparison With Bone Fragility
|
N/A | |
Completed |
NCT01136616 -
CT Analysis of Structural Buttresses in the Traumatised Nose
|
Phase 2 | |
Completed |
NCT02090972 -
The Impact of Opioids in Fractures - a Case Control Study
|
N/A | |
Recruiting |
NCT02237040 -
A New Treatment Protocol for Paediatric Mandibular Condylar Fractures
|
N/A | |
Completed |
NCT00872105 -
Conservative Treatment Versus Operative Plate Fixation for Acute, Displaced Fractures of the Distal Clavicle
|
N/A | |
Completed |
NCT00652548 -
Use of Ultrasound to Evaluate Clavicle Fractures in Pediatric Patients
|
N/A |